We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although the FDA’s deadline for placing bar codes on drug labels is imminent, there is no consensus about what the rate of compliance will be, an industry expert says.
Radio frequency identification (RFID) tags remain the primary technology for pharmaceutical firms seeking to combat counterfeiting, but other technologies could provide some competition, according to experts at a recent conference.
Pfizer is facing a federal class action lawsuit alleging the company defrauded insurance plans and the federal government by improperly marketing its top-selling Lipitor.
The Justice Department (DOJ) is overreaching in its off-label enforcement practices, undermining legitimate industry research and conflicting with other federal agencies, a leading industry attorney says.
Genentech and Biogen Idec allegedly paid doctors to promote an off-label use of their non-Hodgkin’s lymphoma drug Rituxan as a treatment for rheumatoid arthritis (RA) and other conditions, according to a citizen petition filed Feb. 24 by a researcher at a Chicago law firm representing a former Genentech employee who has sued the company.
Pharmaceutical firms are beginning to accept the electronic common technical document (eCTD), but full adoption “still has a long way to go,” an FDA official said.
The Justice Department (DOJ) is overreaching in its off-label enforcement practices, undermining legitimate industry research and conflicting with other federal agencies, a leading industry attorney says.